Reliability and validity of the Beck Depression Inventory in patients with Parkinson's disease
ABSTRACT We evaluated the validity, reliability, and potential responsiveness of the Beck Depression Inventory (BDI) in patients with Parkinson's disease (PD). In part 1 of the study, 92 patients with PD underwent a structured clinical interview for DSM major depression and based on this patients were considered depressed (PD-D) or nondepressed (PD-ND). Subsequently, patients filled in the BDI. In part 2, a postal survey consisting the BDI was performed in 185 PD patients and 112 controls. Test-retest reliability was assessed in 60 PD patients. The factor analysis revealed a cognitive-affective and a somatic factor. Cronbachs alpha for the BDI was 0.88. Mean BDI indicated significant differences (P<0.001) between the PD and control group, between the PD-ND and PD-D group, and between PD-ND and control group. In part 1, the receiver operating characteristic curves showed that the area under the curve for the total BDI was 0.88. A cutoff was calculated for the BDI (14/15) that had the highest sum of sensitivity (0.71) and specificity (0.90). In part 2, the test-retest reliability for the BDI total score was 0.89 (intraclass correlation coefficient). The smallest real difference was 3.3 for the total BDI. The BDI is a valid, reliable, and potential responsive instrument to assess the severity of depression in PD. However, an adjusted cutoff is recommended.
Full-textDOI: · Available from: Johan Marinus, Aug 29, 2015
- SourceAvailable from: Carlo Caltagirone
[Show abstract] [Hide abstract]
- "Previous findings in PD patients have shown an association between on/off states, fluctuations of mood and anxiety symptoms , and a potential negative influence of affective disorders on cognitive performance  . Therefore, the State and Trait Anxiety Inventory-State Anxiety (STAY-S)  and the Beck Depression Inventory (BDI)   were administered to both PD and healthy participants in the two experimental sessions. "
ABSTRACT: previous data suggest that i) dopamine modulates the ability to implement non-routine schemata and updating operations (flexibility processes) and that ii) dopamine-related improvement may be related to baseline dopamine levels in target pathways (inverted U-shaped hypothesis). to investigate above hypotheses in individuals with Parkinson's disease (PD). twenty PD patients were administered tasks varying as to flexibility load in two treatment conditions: i) "off" condition, about 18~hours after dopamine dose; ii) "on" condition, after dopamine administration. PD patients were separated into two groups: low performers (i.e., performance on Digit Span Backward below the sample mean) and high performers (i.e. performance above the mean). Twenty healthy individuals performed the tasks in two sessions without taking drugs. passing from the "off" to the "on" state, only low performer PD patients significantly improved their performance on high-flexibility measures (interference condition of the Stroop test; p< 0.05); no significant effect was found on low-flexibility tasks. these findings document that high-flexibility processes are sensitive to dopamine neuromodulation in the early phases of PD. This is in line with the hypothesis that striatal dopamine pathways, affected early by PD, are precociously implicated in the expression of cognitive disorders in these individuals.Behavioural neurology 09/2013; 2014(16). DOI:10.3233/BEN-130354 · 1.64 Impact Factor
[Show abstract] [Hide abstract]
- "Nevertheless, a recent large-scale study (Trenkwalder et al. 2011a) in patients selected for having unsatisfactory early morning motor-symptom control at any PD stage, with or without levodopa, constitutes the first double-blind, placebo-controlled investigation of the effects of a CDD strategy on both motor and nonmotor deficits. At 12 weeks, mean early morning motor dysfunction, mean sleep disturbance, and depressive symptomatology [as measured by UPDRS (Fahn et al. 1987), the PD sleep scale (PDSS) (Trenkwalder et al. 2011b), and the Beck depression inventory (BDI) (Visser et al. 2006), respectively] showed significantly greater improvements in the active-treatment group. Rotigotine has been re-introduced in the US market as a new formulation that may be more stable than the original. "
ABSTRACT: The complications of long-term levodopa therapy for Parkinson's disease (PD) include motor fluctuations, dyskinesias, and also nonmotor fluctuations-at least equally common, but less well appreciated-in autonomic, cognitive/psychiatric, and sensory symptoms. In seeking the pathophysiologic mechanisms, the leading hypothesis is that in the parkinsonian brain, intermittent, nonphysiological stimulation of striatal dopamine receptors destabilizes an already unstable system. Accordingly, a major goal of PD treatment in recent years has been the attainment of continuous dopaminergic stimulation (CDS)-or, less theoretically (and more clinically verifiable), continuous drug delivery (CDD). Improvements in the steadiness of the plasma profiles of various dopaminergic therapies may be a signal of progress. However, improvements in plasma profile do not necessarily translate into CDS, or even into CDD to the brain. Still, it is reassuring that clinical studies of approaches to CDD have generally been positive. Head-to-head comparative trials have often failed to uncover evidence favoring such approaches over an intermittent therapy. Nevertheless, the findings among recipients of subcutaneous apomorphine infusion or intrajejunal levodopa/carbidopa intestinal gel suggest that nonmotor PD symptoms or complications may improve in tandem with motor improvement. In vivo receptor binding studies may help to determine the degree of CDS that a dopaminergic therapy can confer. This may be a necessary first step toward establishing whether CDS is, in fact, an important determinant of clinical efficacy. Certainly, the complexities of optimal PD management, and the rationale for an underlying strategy such as CDS or CDD, have not yet been thoroughly elucidated.Journal of Neural Transmission 03/2013; 120(9). DOI:10.1007/s00702-013-0981-5 · 2.87 Impact Factor
[Show abstract] [Hide abstract]
- "Depressive symptoms of parents with CMC, also referred to as parental depression, were determined with the Beck Depression Inventory (21 items; 4-point scale from 0 0 I do not feel like a failure to 3 0 I feel I am a complete failure as a person, α00.87) (Beck et al. 1961; Visser et al. 2006; Yin and Fan 2000). "
ABSTRACT: This article was inspired by Rolland's Family Systems-Illness (FSI) model, aiming to predict adolescent stress as a function of parental illness type. Ninety-nine parents with a chronic medical condition, 82 partners, and 158 adolescent children (51 % girls; mean age = 15.1 years) participated in this Dutch study. The Dutch Stress Questionnaire for Children was used to measure child report of stress. Ill parents completed the Beck Depression Inventory. Children filled in a scale of the Inventory of Parent and Peer Attachment measuring the quality of parent attachment. Both parents filled in the Parent-Child-Interaction Questionnaire-Revised. We conducted multilevel regression analyses including illness type, the ill parent's depressive symptoms, family functioning (quality of marital relationship, parent-child interaction, and parent attachment), and adolescents' gender and age. Four regression analyses were performed separately for each illness type as defined by disability (Model 1), and onset (Model 2), course (Model 3), and outcome of illness (Model 4). In all models, higher adolescent stress scores were linked to lower quality of parent-child interaction and parent attachment, and adolescents' female gender. The four models explained approximately 37 % of the variance in adolescent stress between individuals and 43-44 % of the variance in adolescent stress between families. Adolescent stress was not related to parental illness type. Our results partially supported the FSI model stating that family functioning is essential in point of child adjustment to parental illness. In the chronic stage of parental illness, adolescent stress does not seem to vary depending on illness type.Journal of Developmental and Physical Disabilities 12/2012; 24(6):591-606. DOI:10.1007/s10882-012-9291-3 · 1.56 Impact Factor